News Agency
The Times

GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation

  • Written by PR Newswire

SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration has approved Dupert®(fulzerasib, GFH925/IBI351)for the treatment of patients with advanced non-small cell...

Read more: GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced...

Commercial Leasing Mistakes That Can Cost Your Business

Signing a commercial lease is a significant commitment, and the mistakes made at the outset of a tenancy can follow a business for the entire duration of the agreement. Many tenants enter lease negotiations without a full understanding of what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion